Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 15/20 | 0.78 |
| ▸ | DRD3 | P35462 | 14/20 | 0.78 |
| ▸ | HTR2A | P28223 | 4/20 | 0.78 |
| ▸ | DRD4 | P21917 | 3/20 | 0.78 |
| ▸ | HTR1A | P08908 | 3/20 | 0.78 |
| ▸ | HTR2C | P28335 | 2/20 | 0.78 |
| ▸ | HTR2B | P41595 | 2/20 | 0.78 |
| ▸ | DRD1 | P21728 | 1/20 | 0.65 |
| ▸ | HTR7 | P34969 | 1/20 | 0.61 |
| ▸ | HTR6 | P50406 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23331418 | 1.00 | DRD2 (0.78) | DRD2DRD3HTR2ADRD4HTR1A | |
| SCHEMBL25106927 | 1.00 | DRD2 (0.78) | DRD2DRD3HTR2ADRD4HTR1A | |
| SCHEMBL29904305 | 1.00 | DRD2 (0.78) | DRD2DRD3HTR2ADRD4HTR1A | |
| SCHEMBL23331609 | 1.00 | DRD2 (0.78) | DRD2DRD3HTR2ADRD4HTR1A | |
| SCHEMBL24689902 | 0.92 | DRD3 (0.66) | DRD2DRD3HTR2ADRD4HTR1A | |
| SCHEMBL24689483 | 0.92 | DRD3 (0.66) | DRD2DRD3HTR2ADRD4HTR1A | |
| SCHEMBL30855313 | 0.87 | DRD2 (1.00) | DRD2DRD3HTR2ADRD4HTR1A | |
| SCHEMBL23331419 | 0.86 | DRD3 (0.59) | DRD2DRD3HTR2ADRD4HTR1A | |
| SCHEMBL25106803 | 0.85 | DRD3 (0.65) | DRD2DRD3HTR2ADRD4HTR1A | |
| SCHEMBL25106664 | 0.82 | DRD3 (0.62) | DRD2DRD3HTR2ADRD4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617759-B2 | Modifier of four-membered ring derivative, preparation method and application thereof | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| CN-118772126-A | Quaternary ring derivative regulator, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-118772125-A | Quaternary ring derivative regulator, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-113056454-B | Quaternary ring derivative regulator, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-08-02 | — | — | CN | disclosed |
| US-20240254109-A1 | SALT CONTAINING PIPERAZINE POLYCYCLIC DERIVATIVE, CRYSTAL FORM THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-08-01 | — | — | US | disclosed |
| CN-117242058-A | Salt containing piperazine polycyclic derivative and crystal form, and preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-12-15 | — | — | CN | disclosed |
| US-20230076435-A1 | MODIFIER OF FOUR-MEMBERED RING DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2023-03-09 | — | — | US | disclosed |
| CN-115246801-A | Free base crystal form containing piperazine polycyclic derivative and preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2022-10-28 | — | — | CN | disclosed |
| EP-4053110-A1 | MODIFIER OF FOUR-MEMBERED RING DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2022-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230076435-A1 | MODIFIER OF FOUR-MEMBERED RING DERIVATIVE, PREPARATION METHOD AND APPLICATION THEREOF | GRM4, GRM5, GRIA4 | DRD2 343/4885DRD3 367/4885HTR2A 67/4885 |
| US-20240254109-A1 | SALT CONTAINING PIPERAZINE POLYCYCLIC DERIVATIVE, CRYSTAL FORM THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF | SLC6A11, GPR35, GPR132 | DRD2 803/4885DRD3 1345/4885HTR2A 414/4885 |
| US-12617759-B2 | Modifier of four-membered ring derivative, preparation method and application thereof | CHRNA6, HTR6, GRM6 | DRD2 202/4885DRD3 204/4885HTR2A 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.